Literature DB >> 9226980

Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?

R J Stephens1, P Hopwood, D J Girling, D Machin.   

Abstract

The assessment of physical symptoms is a key component of quality of life studies in palliative care, but is often hampered by missing data from patient-completed questionnaires. In two large multicentre randomized trials of palliative treatment conducted by the Medical Research Council Lung Cancer Working Party, Involving over 700 patients, patients completed Rotterdam Symptom Checklists and doctors reported on eleven of the same physical symptoms at each assessment, using the same 4-point severity scale. Ratings by doctors and patients were compared with respect to compliance, severity, and outcomes for the respective trials. Doctors provided more data than patients: 66% vs. 52% in the first 6 months in one trial, 58% vs. 61% in the other. Comparisons of over 33,000 symptom assessments showed 78% complete agreement between doctor and patient, 18% disagreement by one, 4% two, and 1% three grades (complete disagreement). There was no change in levels of agreement over time, but increasing disagreement with increasing symptom severity, and a consistent bias towards doctors underestimating severity. Nevertheless, the two methods of data collection resulted in similar between-treatment conclusions. Therefore, in randomized trials the doctors' assessments of key physical symptoms may be sufficient for the between-treatment comparison. However, the fact that doctors underestimate symptom severity 15% of the time has important implications for palliative interventions.

Entities:  

Mesh:

Year:  1997        PMID: 9226980     DOI: 10.1023/a:1026458604826

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  20 in total

1.  Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.

Authors:  F R Macbeth; J J Bolger; P Hopwood; N M Bleehen; J Cartmell; D J Girling; D Machin; R J Stephens; A J Bailey
Journal:  Clin Oncol (R Coll Radiol)       Date:  1996       Impact factor: 4.126

2.  Assessing the quality of life--a study in newly-diagnosed breast cancer patients.

Authors:  P A Ganz; C A Schag; H L Cheng
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

3.  Quality of life in cancer patients. Who measures what?

Authors:  C A Presant
Journal:  Am J Clin Oncol       Date:  1984-10       Impact factor: 2.339

4.  Correlation of patient and caregiver ratings of cancer pain.

Authors:  S A Grossman; V R Sheidler; K Swedeen; J Mucenski; S Piantadosi
Journal:  J Pain Symptom Manage       Date:  1991-02       Impact factor: 3.612

Review 5.  The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review.

Authors:  M A Sprangers; N K Aaronson
Journal:  J Clin Epidemiol       Date:  1992-07       Impact factor: 6.437

6.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

7.  Using proxies to evaluate quality of life. Can they provide valid information about patients' health status and satisfaction with medical care?

Authors:  A M Epstein; J A Hall; J Tognetti; L H Son; L Conant
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

8.  Who should measure quality of life, the doctor or the patient?

Authors:  M L Slevin; H Plant; D Lynch; J Drinkwater; W M Gregory
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

9.  Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

10.  Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more
  58 in total

1.  Who should measure quality of life?

Authors:  J Addington-Hall; L Kalra
Journal:  BMJ       Date:  2001-06-09

2.  Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire.

Authors:  Kathleen W Wyrwich; William M Tierney; Fredric D Wolinsky
Journal:  Qual Life Res       Date:  2002-02       Impact factor: 4.147

Review 3.  Management of lung cancer.

Authors:  A Melville; A Eastwood
Journal:  Qual Health Care       Date:  1998-09

4.  Best practice in symptom assessment: a review.

Authors:  E McColl
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

5.  Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.

Authors:  Naohiko Inoue; Hideyuki Ishida; Motohiko Sano; Tohru Kishino; Norimichi Okada; Kensuke Kumamoto; Keiichiro Ishibashi
Journal:  Int J Clin Oncol       Date:  2011-08-11       Impact factor: 3.402

6.  A new index of priority symptoms in advanced ovarian cancer.

Authors:  Sally E Jensen; Sarah K Rosenbloom; Jennifer L Beaumont; Amy Abernethy; Paul B Jacobsen; Karen Syrjala; David Cella
Journal:  Gynecol Oncol       Date:  2010-11-13       Impact factor: 5.482

7.  Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.

Authors:  Jennifer Le-Rademacher; Rahul Kanwar; Drew Seisler; Deirdre R Pachman; Rui Qin; Alexej Abyzov; Kathryn J Ruddy; Michaela S Banck; Ellen M Lavoie Smith; Susan G Dorsey; Neil K Aaronson; Jeff Sloan; Charles L Loprinzi; Andreas S Beutler
Journal:  Support Care Cancer       Date:  2017-06-20       Impact factor: 3.603

Review 8.  [The benefits of using patient-reported outcomes in cancer treatment: an overview].

Authors:  Lisa M Wintner; Johannes M Giesinger; Georg Kemmler; Monika Sztankay; Anne Oberguggenberger; Eva-Maria Gamper; Barbara Sperner-Unterweger; Bernhard Holzner
Journal:  Wien Klin Wochenschr       Date:  2012-04-27       Impact factor: 1.704

9.  Palliative care in primary care: a study to determine whether patients and professionals agree on symptoms.

Authors:  Gail Ewing; Margaret Rogers; Stephen Barclay; Janet McCabe; Anna Martin; Malcolm Campbell; Chris Todd
Journal:  Br J Gen Pract       Date:  2006-01       Impact factor: 5.386

10.  A randomized trial of weekly symptom telemonitoring in advanced lung cancer.

Authors:  Susan E Yount; Nan Rothrock; Michael Bass; Jennifer L Beaumont; Deborah Pach; Thomas Lad; Jyoti Patel; Maria Corona; Rebecca Weiland; Katherine Del Ciello; David Cella
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.